← Back to search

Aerovate Therapeutics Inc

AVTE · NASDAQ

Research and Development in Biotechnology

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

ESG Scores

Overall ESG
5.0
Environmental
6.5
Social
3.7
Governance
5.2

Gender Diversity

Female Directors0.2857%
CEO GenderMale